Trial Profile

A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Focus Adverse reactions; Registrational
Sponsors Pharmacyclics

Most Recent Events

24 Mar 2020 Results from NCT01105247 and NCT01109069, evaluating Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia, published in the Clinical Cancer Research
04 Sep 2019 Status changed from active, no longer recruiting to completed.
04 Dec 2018 Results assessing 7-year follow up of ibrutinib in first line and relapsed or refractory patients with chronic lymphocytc leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com